Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Emerging cancer risks in BRCA2 pathogenic germline variant carriers

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout


  1. Li S, Silvestri V, Leslie G, Rebbeck TR, Neuhausen SL, Hopper JL, et al. Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. JCO. 2022;25;JCO.21.02112.

  2. Momozawa Y, Sasai R, Usui Y, Shiraishi K, Iwasaki Y, Taniyama Y, et al. Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants. JAMA Oncol. 2022;8:871–8.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Usui Y, Taniyama Y, Endo M, Koyanagi YN, Kasugai Y, Oze I, et al. Helicobacter pylori, Homologous-Recombination Genes, and Gastric Cancer. N Engl J Med. 2023;388:1181–90.

    Article  CAS  PubMed  Google Scholar 

  4. Wineland D, Le AN, Hausler R, Kelly G, Barrett E, Desai H, et al. Biallelic BRCA Loss and Homologous Recombination Deficiency in Nonbreast/Ovarian Tumors in Germline BRCA1/2 Carriers. JCO Precis Oncol. 2023;7:e2300036.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Benusiglio PR, Fallet V, Sanchis-Borja M, Coulet F, Cadranel J. Lung cancer is also a hereditary disease. Eur Respir Rev. 2021;30:210045.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Ji X, Mukherjee S, Landi MT, Bosse Y, Joubert P, Zhu D, et al. Protein-altering germline mutations implicate novel genes related to lung cancer development. Nat Commun. 2020;11:2220.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Yap TA, Ashok A, Stoll J, Mauer E, Nepomuceno VM, Blackwell KL, et al. Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines. JAMA Netw Open. 2022;5:e2213070.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Diossy M, Sztupinszki Z, Borcsok J, Krzystanek M, Tisza V, Spisak S, et al. A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures. npj Precis Onc. 2021;5:1–8.

    Article  Google Scholar 

  9. Rifkin AS, Less EM, Wei J, Shi Z, Zheng SL, Helfand BT, et al. Association of Reported Candidate Monogenic Genes With Lung Cancer Risk. Clin Lung Cancer. 2023;24:313–21.

    Article  CAS  PubMed  Google Scholar 

  10. Kuzbari Z, Bandlamudi C, Loveday C, Garrett A, Mehine M, George A, et al. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations. Ann Oncol. 2023;34:215–27.

    Article  CAS  PubMed  Google Scholar 

  11. Patel AP, Wang M, Fahed AC, Mason-Suares H, Brockman D, Pelletier R, et al. Association of Rare Pathogenic DNA Variants for Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome, and Lynch Syndrome With Disease Risk in Adults According to Family History. JAMA Netw Open. 2020;3:e203959.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Li S, Silvestri V, Rebbeck TR, Neuhausen SL, Hopper JL, Nielsen HR, et al. Reply to V. Fallet et al. JCO. 2022;40:2509–10.

    Article  Google Scholar 

  13. Adams SJ, Stone E, Baldwin DR, Vliegenthart R, Lee P, Fintelmann FJ. Lung cancer screening. Lancet. 2023;401:390–408.

    Article  PubMed  Google Scholar 

  14. Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69:2093–112.

    Article  PubMed  Google Scholar 

Download references



No specific funding was involved.

Author information

Authors and Affiliations



PB reviewed the literature and wrote the first draft. PB, AD, VF and JC discussed the evidence, made carrier management proposals, revised the paper and approved the final version.

Corresponding author

Correspondence to Patrick R. Benusiglio.

Ethics declarations

Competing interests

PRB has received honoraria from AstraZeneca and MSD, the manufacturers or olaparib, a drug that targets BRCA2-deficient cancers.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Benusiglio, P.R., Dardenne, A., Fallet, V. et al. Emerging cancer risks in BRCA2 pathogenic germline variant carriers. Eur J Hum Genet 31, 1355–1356 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links